"Porosome Therapeutics has announced a significant breakthrough in Alzheimer’s disease research, focusing on secretory dysfunction and new therapeutic approaches.
Alzheimer’s disease is characterised by neuronal loss due to secretory and metabolic defects, leading to mitochondrial dysfunction and neurotransmitter depletion. Research has shown that beta-amyloid alters proteins within the porosome complex, suggesting that introducing functional porosomes into affected neurons may improve brain function and cognitive abilities.
The company’s latest findings indicate that restoring porosome function, combined with small molecule and peptide therapy, may not only slow disease progression but also potentially reverse early-stage pathology.
This approach moves beyond traditional methods that primarily target amyloid accumulation.
Research has identified how beta-amyloid (Aβ) disrupts essential protein interactions within the neuronal porosome complex, leading to impaired neurotransmitter release. Immunocytochemistry studies on human brain tissue have confirmed these findings.
By using artificial intelligence-driven tools, the company has gained molecular-level insights into how neurosecretion is affected in Alzheimer’s, advancing the potential for innovative treatment options.
These therapies target both secretory dysfunction and mitochondrial defects, which are key contributors to Alzheimer’s disease. Preclinical studies have validated this approach, demonstrating its potential to restore neurotransmitter release, communication, and plasticity in affected neurons.
Further studies have highlighted the role of mitochondrial proteins in cellular function and their link to porosomes. This research aims to enhance understanding of neurodegenerative diseases and reshape treatment strategies.
Recent preclinical trials have shown promising results, suggesting this method could offer a more effective alternative to conventional therapies, which often focus on symptom management rather than addressing the root causes.
The company’s research extends beyond Alzheimer’s, with ongoing work in conditions such as cystic fibrosis.